Orkla stock rises 1.18 percent on buyback plan

Orkla stock (ISIN not supplied) rose 1.18 percent to NOK 94.35 on the Oslo Bors on September 24, 2026, at 1:08 p.m. CEST. The move followed a buyback authorization worth up to NOK 4.0 billion, while the latest quarter combined flat underlying sales with higher underlying profitability.

Buyback sets a capital return test

Orkla plans to repurchase up to 80 million shares for as much as NOK 4.0 billion, with the program starting on September 22, 2026. TradingView reported that Orkla intends to cancel repurchased shares, which would reduce the share count if the full program is executed.

The authorization gives Orkla a defined capital allocation lever after a period of weaker reported sales. Its effect on earnings per share will depend on the pace of purchases and the final number of shares canceled, making execution more important than the headline size alone.

Q2 margin holds above 10 percent

Orkla's Q2 2026 reported revenue declined 5 percent, while underlying revenue was flat and adjusted EBIT increased 2.5 percent. The EBIT margin was 10.5 percent, according to the Q2 earnings-call transcript published by Yahoo Finance.

The contrast between a 5 percent reported revenue decline and 2.5 percent adjusted EBIT growth points to currency effects and operating discipline as the central quarterly tension. Orkla's investor page identifies the figures as part of its Q2 2026 reporting cycle dated August 20, 2026, and describes the result as moderate underlying profit growth.

Stock remains below yearly high

At NOK 94.35 on September 24, 2026, Orkla traded 28.1 percent below its 52-week high of NOK 131.20 and 4.8 percent above its 52-week low of NOK 90.00. The market capitalization was NOK 92,247,398,645 on the same date.

The buyback provides a measurable shareholder-return framework, while the Q2 figures show that margin resilience has so far offset currency pressure on reported revenue. Orkla's next valuation signal will come from whether underlying profit growth continues alongside a recovery in reported sales.